Pfizer plans to submit data about its COVID-19 vaccine for children ages 5 to 11 to the Food and Drug Administration "pretty soon," CEO Albert Bourla told ABC's "This Week" on Sunday.

Why it matters: The start of the school year saw a rise in COVID-19 infections among kids, and heightened the focus on when the vaccine will be available for children.

• Earlier this week, Pfizer announced that results from its pediatric trial indicate that its vaccine — in a smaller dosage than given to adults — is safe and effective for children ages 5 to 11.

What he's saying: "I think we're going to submit this data pretty soon. It's a question of days, not weeks," Bourla said.

• "Then it is up to the FDA to be able to review the data and come to their conclusions, and approve it or not."
• "If they approve it, we will be ready with our manufacturing to provide this new formulation of the vaccine," Bourla said./Axios